⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
3,255
Total Claims
$1.9M
Drug Cost
405
Beneficiaries
$4,811
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+22%
Cost per patient vs peers
$4,811 vs $3,933 avg
+17%
Brand preference vs peers
60.0% vs 51.2% avg
Brand vs Generic
40% generic
Brand: 1,775 claims · $1.9M
Generic: 1,181 claims · $39K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 150 | $293K |
| Semaglutide | 135 | $236K |
| Insulin Lispro | 131 | $189K |
| Insulin Glargine,hum.Rec.Anlog | 221 | $168K |
| Insulin Aspart | 122 | $147K |
| Empagliflozin | 84 | $114K |
| Semaglutide | 63 | $101K |
| Liraglutide | 31 | $72K |
| Tirzepatide | 21 | $45K |
| Insulin Aspart | 29 | $43K |
| Dapagliflozin Propanediol | 33 | $42K |
| Insulin Glargine,hum.Rec.Anlog | 26 | $41K |
| Insulin Degludec | 26 | $37K |
| Insulin Glargine,hum.Rec.Anlog | 35 | $37K |
| Liraglutide | 12 | $34K |
Prescribing Profile
Patient Profile
75
Avg Age
55%
Female
1.83
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About